Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

CJ CheilJedang is a core subsidiary in charge of the food and bioengineering business Unit of the CJ Group. It has led the development of the Korean food industry for the past 60 years, and contributed to the development of the bioengineering industry as the nation’s top food originated company. After being launched in 1953 as a food ingredient company, continuously extended its business to processed foods. In 2007, CJ CheilJedang divided out as a subsidiary company to concentrate on the food and bioengineering business.

iNtRON Biotechnology, Inc. engages in the development of super-bacteria treatment, antibiotics alternatives, bio new drug, molecular diagnostics and artificial blood. Its products include anti-bacterial agents, identification kits, research reagents and kits. The company was founded on January 18, 1999 and is headquartered in Seongnam-si, South Korea.

Thrombolytic Science is focused on developing a proprietary product, M5, a mutant of pro-urokinase (proUK). M5 is a thrombolytic that follows a different paradigm than tPA, has superior efficacy and is accompanied by little bleeding risk.

Omrix Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets biological products for the biosurgical and immunotherapy markets.

Seikagaku Corp. manufactures pharmaceuticals and medical devices with glycoconjugates; specifically, glycosaminoglycans (GAG) such as hyaluronic acid; as well as enzymes that act on GAG. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection. The LAL segment manufactures and sells endotoxin-detecting reagents in Japan and overseas. The company was founded on June 2, 1947 and is headquartered in Tokyo, Japan.

Developer of a point-of-care patient screening platform designed to detect Staphylococcus aureus and a broad panel of dangerous and evolving pathogens. The company's patient screening platform has the potential to fundamentally alter the market for detecting dangerous pathogens through a panel of in-vitro diagnostics, enabling hospitals, nursing homes and other healthcare facilities to prevent the spread of disease causing organisms and significantly impact the clinical care of patients.

FutureChem Co., Ltd. engages in the manufacture of medical products. Its products include radiopharmaceutical, automation module, chemicals, linkers (bioconjugation), ionic liquids and custom synthesis. In addition, it also engages in the research and development of radioisotope labeling. The company was founded on August 13, 2001 and is headquartered in Seoul, South Korea.

Horiba ABX SA specializes in the design and manufacture of automated in vitro diagnostics systems used in hematology and clinical chemistry. The company has production plants in Montpellier, Kyoto, and Sao Paulo. The firm was founded in 1983 and is headquartered in Montpellier, France.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Agalimmune Ltd., a subsidiary of BioLineRx Ltd., is a British company located in London that develops anti-cancer immunotherapy technology. It was founded by Graham Griffiths. Mike Westby is currently the CEO of the firm. BioLineRx Ltd. acquired Agalimmune Ltd. on March 23, 2017 for $6.05 million.

Oncolytics Biotech focuses the research and development efforts on the development of REOLYSIN, the cancer therapeutic. The product for human use, REOLYSIN is developed from the reovirus. The virus has been demonstrated to replicate in the tumour cells bearing an activated Ras pathway. The Ras protein is a regulator of cell growth and differentiation. It transmits signals from the cell's surface, through growth factor receptors, to downstream elements, which are in turn relayed to the nucleus. The transmission of signals from the cell surface to the cell's nucleus is referred to as the signal transduction. The wholly owned subsidiaries of the company include Oncolytics Biotech (Barbados) Inc. and Oncoltics Biotech (US) Inc. In April 2009, the Company completed the acquisition of an inactive private company. Oncolytics Biotech was founded on 1988 and is based in Calgary, Alberta, Canada.

Baxter AG, part of Baxter International, Inc., is a company headquartered in Volketswell, Switzerland. The firm wholesales pharmaceutical products.

Shenzhen Tianda Kang Genetic Engineering Co., Ltd., established on 2001-11-22, Business scope includes general business items:Gene Therapy Drug Research,to develop,and related technical advice,Technical service and own technology transfer(No country restrictions,Prohibited items).,The licensing program is:

Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France.

Pasteur Sanofi Diagnostics, part of Bio-Rad Laboratories, Inc., is a company headquartered in France that develops and manufactures clinical diagnostic kits.